7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Uremia D014511 33 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Hofbauer LC and Heufelder AE The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. 2001 Arthritis Rheum. pmid:11229454
Leach RJ et al. The genetics of Paget's disease of the bone. 2001 J. Clin. Endocrinol. Metab. pmid:11231972
Hofbauer LC and Heufelder AE [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. 2001 Dtsch. Med. Wochenschr. pmid:11233883
Bolon B et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. 2001 Mol. Ther. pmid:11237676
Sasaki N et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. 2001 Nephrol. Dial. Transplant. pmid:11239019
Takeuchi T et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. 2001 Biochem. Pharmacol. pmid:11239501
Mori K et al. Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. 2001 Cell. Immunol. pmid:11243701
Michigami T et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. 2001 Cancer Res. pmid:11245477
Wada N et al. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. 2001 J. Periodont. Res. pmid:11246705
Lories RJ and Luyten FP Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. 2001 Clin. Rheumatol. pmid:11254237
Chen D et al. ELISA methodology for detection of modified osteoprotegerin in clinical studies. 2001 Clin. Chem. pmid:11274028
Collin-Osdoby P et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. 2001 J. Biol. Chem. pmid:11274143
Mackie PS et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. 2001 Br. J. Cancer pmid:11286476
Wise GE et al. Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. 2001 Clin Anat pmid:11301468
Brown JM et al. Osteoprotegerin and rank ligand expression in prostate cancer. 2001 Urology pmid:11306358
Fukagawa M et al. [PTH and bone metabolism in chronic dialysis patients]. 2001 Rinsho Byori pmid:11307321
Horowitz MC et al. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. 2001 Cytokine Growth Factor Rev. pmid:11312114
Hofbauer LC et al. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. 2001 J. Rheumatol. pmid:11327234
Atkins GJ et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. 2001 Bone pmid:11336917
Komine M et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. 2001 Bone pmid:11344046
Lin DL et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. 2001 Prostate pmid:11351351
Sparks AB et al. Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. 2001 Calcif. Tissue Int. pmid:11351498
Disthabanchong S and González EA Regulation of bone cell development and function: implication for renal osteodystrophy. 2001 J. Investig. Med. pmid:11352181
Kotake S et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. 2001 Arthritis Rheum. pmid:11352231
Saika M et al. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. 2001 Endocrinology pmid:11356664
Luger NM et al. Osteoprotegerin diminishes advanced bone cancer pain. 2001 Cancer Res. pmid:11358823
Goltzman D Osteolysis and cancer. 2001 J. Clin. Invest. pmid:11375409
Zhang J et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. 2001 J. Clin. Invest. pmid:11375413
Kostenuik PJ and Shalhoub V Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. 2001 Curr. Pharm. Des. pmid:11375772
Kanzaki H et al. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. 2001 J. Dent. Res. pmid:11379890
Hein GE [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. 2001 Z Rheumatol pmid:11383046
Morony S et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. 2001 Cancer Res. pmid:11389072
Abu-Amer Y IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. 2001 J. Clin. Invest. pmid:11390419
Kon T et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. 2001 J. Bone Miner. Res. pmid:11393777
Fazzalari NL et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. 2001 J. Bone Miner. Res. pmid:11393778
Kim KJ et al. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. 2001 J. Biomed. Mater. Res. pmid:11410897
Haynes DR et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 Rheumatology (Oxford) pmid:11426018
Szulc P et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. 2001 J. Clin. Endocrinol. Metab. pmid:11443182
Sakiyama H et al. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. 2001 J. Bone Miner. Metab. pmid:11448014
Choi Y et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. 2001 Eur. J. Immunol. pmid:11449372
Thirunavukkarasu K et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. 2001 J. Biol. Chem. pmid:11451955
Seck T et al. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. 2001 Eur. J. Endocrinol. pmid:11454517
Burguera B et al. Leptin reduces ovariectomy-induced bone loss in rats. 2001 Endocrinology pmid:11459801
Yamagishi T et al. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. 2001 Endocrinology pmid:11459812
Furuya D et al. Immuno-PCR assay for homodimeric osteoprotegerin. 2001 Clin. Chem. pmid:11468243
Thomas GP et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. 2001 J. Endocrinol. pmid:11479141
Hofbauer LC and Heufelder AE Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. 2001 J. Mol. Med. pmid:11485016
Hofbauer LC and Schoppet M Osteoprotegerin: a link between osteoporosis and arterial calcification? 2001 Lancet pmid:11498208
Sakai A et al. 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. 2001 J. Bone Miner. Metab. pmid:11498729
Ikeda T et al. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. 2001 J. Bone Miner. Res. pmid:11499864

Table of Content